187 related articles for article (PubMed ID: 22463589)
1. High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer.
D' Alterio C; Portella L; Ottaiano A; Rizzo M; Carteni G; Pignata S; Facchini G; Perdona S; Di Lorenzo G; Autorino R; Franco R; La Mura A; Nappi O; Castello G; Scala S
Curr Cancer Drug Targets; 2012 Jul; 12(6):693-702. PubMed ID: 22463589
[TBL] [Abstract][Full Text] [Related]
2. Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy.
del Puerto-Nevado L; Rojo F; Zazo S; Caramés C; Rubio G; Vega R; Chamizo C; Casado V; Martínez-Useros J; Rincón R; Rodríguez-Remírez M; Borrero-Palacios A; Cristóbal I; Madoz-Gúrpide J; Aguilera O; García-Foncillas J
Br J Cancer; 2014 May; 110(11):2700-7. PubMed ID: 24786599
[TBL] [Abstract][Full Text] [Related]
3. Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma.
Izzedine H; Derosa L; Le Teuff G; Albiges L; Escudier B
Ann Oncol; 2015 Jun; 26(6):1128-1133. PubMed ID: 25795198
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.
Motzer RJ; Ravaud A; Patard JJ; Pandha HS; George DJ; Patel A; Chang YH; Escudier B; Donskov F; Magheli A; Carteni G; Laguerre B; Tomczak P; Breza J; Gerletti P; Lechuga M; Lin X; Casey M; Serfass L; Pantuck AJ; Staehler M
Eur Urol; 2018 Jan; 73(1):62-68. PubMed ID: 28967554
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
Xie M; He CS; Huang JK; Lin QZ
Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
7. Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib.
Abel EJ; Culp SH; Tannir NM; Tamboli P; Matin SF; Wood CG
Eur Urol; 2011 Dec; 60(6):1273-9. PubMed ID: 21784574
[TBL] [Abstract][Full Text] [Related]
8. First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†.
Ravaud A; Oudard S; De Fromont M; Chevreau C; Gravis G; Zanetta S; Theodore C; Jimenez M; Sevin E; Laguerre B; Rolland F; Ouali M; Culine S; Escudier B
Ann Oncol; 2015 Jun; 26(6):1123-1128. PubMed ID: 25802238
[TBL] [Abstract][Full Text] [Related]
9. Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma.
Garcia-Donas J; Leandro-García LJ; González Del Alba A; Morente M; Alemany I; Esteban E; Arranz JA; Climent MA; Gallardo E; Castellano DE; Bellmunt J; Mellado B; Puente J; Moreno F; Font A; Hernando S; Robledo M; Rodríguez-Antona C
Ann Oncol; 2013 Sep; 24(9):2409-14. PubMed ID: 23788753
[TBL] [Abstract][Full Text] [Related]
10. Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis.
De Giorgi U; Scarpi E; Sacco C; Aieta M; Lo Re G; Sava T; Masini C; De Vincenzo F; Baldazzi V; Camerini A; Fornarini G; Burattini L; Rosti G; Ferrari V; Moscetti L; Chiuri VE; Luzi Fedeli S; Amadori D; Basso U
Clin Genitourin Cancer; 2014 Jun; 12(3):182-9. PubMed ID: 24369790
[TBL] [Abstract][Full Text] [Related]
11. Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib.
Cebrián A; Gómez Del Pulgar T; Méndez-Vidal MJ; Gonzálvez ML; Lainez N; Castellano D; García-Carbonero I; Esteban E; Sáez MI; Villatoro R; Suárez C; Carrato A; Munárriz-Ferrándiz J; Basterrechea L; García-Alonso M; González-Larriba JL; Perez-Valderrama B; Cruz-Jurado J; González Del Alba A; Moreno F; Reynés G; Rodríguez-Remírez M; Boni V; Mahillo-Fernández I; Martin Y; Viqueira A; García-Foncillas J
Sci Rep; 2017 Jan; 7():41371. PubMed ID: 28117391
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients.
Dornbusch J; Walter M; Gottschalk A; Obaje A; Junker K; Ohlmann CH; Meinhardt M; Zacharis A; Zastrow S; Schoffer O; Grimm MO; Klug SJ; Wirth MP; Fuessel S
J Cancer Res Clin Oncol; 2016 Jun; 142(6):1171-82. PubMed ID: 26935927
[TBL] [Abstract][Full Text] [Related]
13. Candidate MicroRNA Biomarkers of Therapeutic Response to Sunitinib in Metastatic Renal Cell Carcinoma: A Validation Study in Patients with Extremely Good and Poor Response.
Kovacova J; Juracek J; Poprach A; Buchler T; Kopecky J; Fiala O; Svoboda M; Slaby O
Anticancer Res; 2018 May; 38(5):2961-2965. PubMed ID: 29715124
[TBL] [Abstract][Full Text] [Related]
14. VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis.
Beuselinck B; Karadimou A; Lambrechts D; Claes B; Wolter P; Couchy G; Berkers J; van Poppel H; Paridaens R; Schöffski P; Méjean A; Verkarre V; Lerut E; Joly F; Lebret T; Gravis G; Deplanque G; Descazeaud A; Leclercq NR; Molinié V; Patard JJ; Teghom C; Elaidi R; Zucman-Rossi J; Oudard S
Acta Oncol; 2014 Jan; 53(1):103-12. PubMed ID: 23421954
[TBL] [Abstract][Full Text] [Related]
15. Angiogenic, inflammatory and immunologic markers in predicting response to sunitinib in metastatic renal cell carcinoma.
Mizuno R; Kimura G; Fukasawa S; Ueda T; Kondo T; Hara H; Shoji S; Kanao K; Nakazawa H; Tanabe K; Horie S; Oya M;
Cancer Sci; 2017 Sep; 108(9):1858-1863. PubMed ID: 28699300
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland.
Purmonen T; Martikainen JA; Soini EJ; Kataja V; Vuorinen RL; Kellokumpu-Lehtinen PL
Clin Ther; 2008 Feb; 30(2):382-92. PubMed ID: 18343276
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
18. Tissue Biomarkers in Predicting Response to Sunitinib Treatment of Metastatic Renal Cell Carcinoma.
Trávníček I; Branžovský J; Kalusová K; Hes O; Holubec L; Pele KB; Ürge T; Hora M
Anticancer Res; 2015 Oct; 35(10):5661-6. PubMed ID: 26408740
[TBL] [Abstract][Full Text] [Related]
19. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.
Garcia-Donas J; Esteban E; Leandro-García LJ; Castellano DE; González del Alba A; Climent MA; Arranz JA; Gallardo E; Puente J; Bellmunt J; Mellado B; Martínez E; Moreno F; Font A; Robledo M; Rodríguez-Antona C
Lancet Oncol; 2011 Nov; 12(12):1143-50. PubMed ID: 22015057
[TBL] [Abstract][Full Text] [Related]
20. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.
Diekstra MH; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; Rodríguez-Antona C; García-Donas J; Rini BI; Guchelaar HJ
Eur Urol; 2015 Oct; 68(4):621-9. PubMed ID: 25930089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]